Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.





Swiss EPFL spin-off EMBION(TM) Technologies S.A. revolutionizes biomass upcycling

08.07.2020
Ecublens (ots) - * New patented solution PREMBIONTM paves the way to antibiotic-free farming
* EMBION(TM)'s rapid-prototyping platform technology pioneers the affordable future of nutrition
EMBION(TM) Technologies S.A., hard-tech, disruptive innovator in plant-based bioactives for the nutrition of the future, announces the market launch of PREMBION(TM). It is the first patented product with complex prebiotic properties for animal nutrition that was created with EMBION's novel platform technology. The spin-off of the Swiss Federal Institute of Technology in Lausanne (EPFL) accelerates nutrition innovation toward increased functionality and greater affordability. It reduces the time from discovery to commercial production by up to 80%. Market introduction tests are currently underway with leading global corporations in the food, feed and drinks sectors.
EMBION provides access to a proprietary platform technology with the aim to revolutionize biomass upcycling and reduce waste via biocatalytic processing. The invention has been first applied in the development of novel bioactives for human and animal health and nutrition, resulting in the patented solution, PREMBION(TM) manufactured from brewers' spent grains.
"Unique fingerprint products, such as our first patented product PREMBION, are the future of the high potential prebiotic ingredients market for microbiome modulation, providing solutions for the growing demand in antibiotic-free farming against antimicrobial resistance. EMBION's rapid prototyping platform technology catalyzes innovation that is essential for building this market," says Georgios Savoglidis, co-founder and CEO of EMBION.
Savoglidis and his team are looking at successful laboratory tests on 20 feedstocks, which have generated 80 new complex bioactives that are ready for immediate commercialization.
"This was a long shot, but the technology is thoroughly built from the ground up to overcome bottlenecks and has the potential to be transformative, starting with nutrition," summarizes Professor Paul J. Dyson, advisory board member of EMBION Technologies S.A. and Professor of Chemistry at EPFL. Dyson supervised the technology invention from its origin as a project funded by the Swiss National Science Foundation (SNSF-NPR66).
Further information about EMBION
Website - www.embiontech.com
Newsroom/Factsheet
Social Media: LinkedIn / Twitter / Facebook
Digital press kit: http://www.ots.at/pressemappe/CH146161/aom
 

Aktien auf dem Radar:Semperit, Frequentis, DO&CO, Rosenbauer, Warimpex, Zumtobel, Wienerberger, Addiko Bank, EVN, Kapsch TrafficCom, AT&S, Lenzing, Deutsche Post, adidas, Fresenius, Wirecard, LINDE, Beiersdorf, Deutsche Bank, MTU Aero Engines, Andritz, voestalpine, HeidelbergCement.


Random Partner

HSBC
HSBC Deutschland ist Teil der HSBC-Gruppe und kann daher auf eines der größten internationalen Netzwerke zugreifen. HSBC Trinkaus & Burkhardt AG beschäftigt in Deutschland über 3.000 Mitarbeiter an 12 Standorten. Das Finanzinstitut kann bei der Emission von Anlagezertifikaten und Hebelprodukten auf mehr als 30 Jahre Erfahrung zurückschauen.

>> Besuchen Sie 56 weitere Partner auf boerse-social.com/partner


Mehr aktuelle OTS-Meldungen HIER